Johannes Jacob Pieter Kastelein, Chief Scientific Officer at NewAmsterdam Pharma Co N.V. (NAMS), sold 300,000 shares at $30.30 ($9.1M) on 2026-03-05, disclosed to the SEC on 2026-03-09.
Open-market sale of $9.1M NAMS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.30 | 104,467 | $3.2M | 34.8% |
| 2 | $30.32 | 94,124 | $2.9M | 31.4% |
| 3 | $30.29 | 101,409 | $3.1M | 33.8% |
| Total | $30.30 avg | 300,000 | $9.1M | 100% |
| Filing → |
| NAMS | SELL | 2026-01-07 | $200K | — | Filing → |
| NAMS | SELL | 2025-08-25 | $3.7M | — | Filing → |
| NAMS | SELL | 2024-03-27 | $4.1M | — | Filing → |